GBM 患者首次复发后他莫昔芬与依托泊苷的对比
他莫昔芬与依托泊苷治疗首次复发多形性胶质母细胞瘤患者的随机对照试验
The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Jacob Easaw, MD, PhD, FRCPC
- 电话号码:780-432-8290
- 邮箱:jay.easaw@ahs.ca
学习地点
-
-
Alberta
-
Edmonton、Alberta、加拿大
- 招聘中
- Cross Cancer Institute
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Histologically proven GBM with progression after previous first line chemoradiotherapy with temozolomide.
-
Progression documented by MRI with at least one bi-dimensionally measurable target lesion with one diameter of at least 10 mm, visible on two or more axial slices 5 mm apart.
-
Not received radiotherapy within the three months before the diagnosis of progression.
-
Stable or decreasing dose of corticosteroids prior to randomization: corticosteroids (dexamethasone) should be given at the lowest dose needed to control symptoms arising from increased intracerebral edema.
-
ECOG performance 0-2 (Appendix 2).
-
Age from 18-65 years.
-
Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test within 72 hours prior to the first dose of study treatment. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes.
-
Patients of childbearing / reproductive potential should use adequate birth control methods, as defined by the investigator, during the study treatment period and for a period of 60 days after the last dose of study drug. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.
Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.
-
Laboratory evaluation obtained within 7 days prior to randomization, with adequate function as defined below:
- ANC ≥ 1.5 x 109/L
- Platelets ≥ 100 x 109/L
- Serum creatinine ≤ 1.5 times ULN
- Total serum bilirubin ≤ 1.5 times ULN
- ALT < 3 times ULN
- AST < 3 times ULN
- Alkaline phosphatase < 3 times ULN
-
Patient must understand and sign an informed consent prior to study registration.
Exclusion Criteria:
- History of another malignancy or a concurrent malignancy (exceptions include patients who have been disease-free for 3 years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ.
- Uncontrolled hypertension (systolic blood pressure >150 mm Hg or diastolic blood pressure >100 mm Hg).
- Any arterial or venous thrombosis up to 6 months before registration.
- Evidence of recent hemorrhage on brain MRI.
- Substantial cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (> New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:他莫昔芬
|
Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously |
|
有源比较器:依托泊苷
|
etoposide 50mg/m2 daily |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
3 month progression-free survival
大体时间:3 months
|
Time between randomization and radiographic or clinical progression leading to change in therapy for recurrent disease or death due to any cause. |
3 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
One-year progression-free survival
大体时间:12 months
|
Time between randomization and radiographic or clinical progression leading to change in therapy for recurrent disease or death due to any cause. |
12 months
|
|
Overall survival
大体时间:Median, 6-month, 1-year, and 2-year OS rates will be measured
|
Time between randomization and death due to any cause. Patients without an event will be censored the last time they were known to be alive. |
Median, 6-month, 1-year, and 2-year OS rates will be measured
|
|
Health-related quality-of-life status
大体时间:Throughout study completion, up to 5 years.
|
Health-related quality-of-life will be assessed using the EORTC QLQ-BN20 brain tumor module questionnaire. This is a self-report questionnaire consisting of 20 items that assess future uncertainty, visual disorder, motor dysfunction, and communication deficit in brain tumor patients |
Throughout study completion, up to 5 years.
|
|
Adverse events
大体时间:Throughout the whole duration of the trial, up to 5 years
|
This includes fatigue, hematologic toxicities (neutropenia, thrombocytopenia, leukopenia, anemia), liver toxicities, hypertension, diarrhea, seizures and thrombosis and will all be recorded. |
Throughout the whole duration of the trial, up to 5 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.